摘要
目的评价不同给药次数的法舒地尔对慢性阻塞性肺疾病(COPD)继发肺动脉高压治疗效果的差异。方法将72例COPD继发肺动脉高压患者随机分为常规治疗组、每日1次组、每日2次组,其中常规治疗组26例,每日1次组25例,每日2次组21例。常规治疗组行吸氧、抗感染、化痰、平喘、强心利尿或无创呼吸机辅助通气等治疗;每日1次组和每日2次组分别在常规治疗基础上加法舒地尔30 mg每天1次和每天2次滴注治疗。比较各组患者治疗前后测定肺动脉收缩压、动脉血二氧化碳分压(PaCO_2)、N末基末端脑钠肽前体(NT-proBNP)水平及住院时间差异。结果用药后3组患者肺动脉收缩压、PaCO_2、NT-proBNP均有不同程度改善,法舒地尔治疗组改善幅度高于常规治疗组(P<0.05)。两两比较中肺动脉收缩压、PaCO_2在常规治疗组与每日1次组、常规治疗组与每日2次组之间存在统计学差异(P<0.05);NT-proBNP仅在常规治疗组与每日2次组之间存在统计学差异(P<0.05)。3组患者住院时间比较,差异无统计学意义。结论法舒地尔能降低COPD继发的肺动脉高压,改善肺通气及右心功能。增加法舒地尔给药次数未发现能进一步降低COPD患者的肺动脉收缩压。
Objective To estimate therapeutic efficacy of difference doses of fasudil on pulmonary hypertension of chronic obstructive pulmonary disease （COPD） patients. Methods Seventy-two patients with COPD were treated with conventional group （26 cases）, fasudil qd group （25 cases） and fasudil bid group （21 cases）. The conventional group received routine treatment, including oxygen uptake, anti-infection, phlegm dissolving, relieving asthma, diuresis, noninvasive ventilation, etc. The fasudil qd group received 30 mg fasudil one time daily in addition to the routine treatment; and the fasudil bid group received twice. We collected pulmonary artery systolic pressure, arterial partial pressure of carbon dioxide （PaCO 2） and NT-proBNP （N-terminal pro-B-type natriuretic peptide） of these patients before and after treatment. Results After treatment, pulmonary artery systolic pressure, PaCO2 and NT-proBNP of all the patients were decreased significantly, which were more in fasudil groups than conventional group （P〈0.05）. There was no significant differences among the three groups in hospital stay. Conclusion Fasudil can reduce pulmonary hypertension secondary to COPD, improve pulmonary ventilation and function of right heart, but can not further reduce pulmonary hypertension of COPD patients when we enlarge fasudil doses.
出处
《当代医学》
2015年第11期111-112,共2页
Contemporary Medicine
关键词
慢性阻塞性肺疾病
肺动脉高压
法舒地尔
Chronic obstructive plumonary disease
Pulmonary hypertension
Fasudil
